The city of Durham, North Carolina, currently has 8 active clinical trials seeking participants for Diabetes research studies.
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
Recruiting
This is a Phase IIb, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus, compared to placebo and active comparator.
Gender:
ALL
Ages:
All
Trial Updated:
02/19/2025
Locations: Research Site, Durham, North Carolina
Conditions: Diabetes Mellitus, Type 2
SPYRAL AFFIRM Global Study of RDN with the Symplicity Spyral RDN System in Subjects with Uncontrolled HTN
Recruiting
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/17/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
iACT for Eating Disorders in Type 1 Diabetes
Recruiting
This project is a randomized controlled trial of iACT, a novel mHealth intervention for eating disorders in type 1 diabetes (ED-T1DM). Participants will be 128 T1DM patients between the ages of 16-45 with binge-purge EDs, including threshold and subthreshold bulimia nervosa, binge eating disorder and purging disorder. Participants will be randomized to either iACT or Usual Care, and complete assessments at baseline and every 3 months for 9 months. The primary outcome of interest is glycemic cont... Read More
Gender:
ALL
Ages:
Between 16 years and 50 years
Trial Updated:
01/14/2025
Locations: Duke University, Durham, North Carolina
Conditions: Type 1 Diabetes, Eating Disorders
Addressing Barriers to Achieving Cardiometabolic Disorders Prevention and Treatment Goals for PLWH in the SE US
Recruiting
This study has 3 aims. Aim 1: Identify social determinants of cardiometabolic health and determine facilitators and modifiable barriers in achieving treatment goals. Aim 2: Assess PLWH knowledge, skills, and confidence for self-management of cardiometabolic disorders. Aim 3: Tailor a self-management support and education intervention with stakeholder input to address barriers to achieving treatment goals for cardiometabolic disorders in PLWH at the study sites.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/18/2024
Locations: Duke University - Duke Study Site, Durham, North Carolina
Conditions: Hypertension, Dyslipidemias, Type 2 Diabetes, HIV-1-infection
Improving Screening and Therapy for Hispanic/Latinx at Risk for CKD
Recruiting
In this study, the investigators will utilize community organizations to screen Hispanics/Latino(a)s for kidney disease, diabetes, and other risk factors, and refer them for care with a PCP. Additionally, the investigators will implement an intervention in local health clinics to assist PCPs with screening and treating patients with diabetes. Completion of the project will hopefully slow progression of kidney disease among Hispanic/Latino(a) patients in Durham, and the information gained will a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Type 2 Diabetes, Chronic Kidney Diseases
Examining the Effects of Vivo on Physical Function and Glycemic Level in Sedentary Older With Prediabetes.
Recruiting
This is a 12-week randomized, controlled trial that seeks to examine the effect of Vivo on 1) change in lower extremity strength defined as number of chair stands done in 30 seconds and 2) change in average glycemic level (HbA1c) compared to a wait list control.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
07/26/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: PreDiabetes, Older Adult, Muscle Loss, Muscle Weakness
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
Recruiting
PRECIDENTD is a randomized, open label, pragmatic clinical trial designed to compare rates of the total number of cardiovascular, kidney, and death events among two alternative treatments for patients with type 2 diabetes (T2D) and either established atherosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD. To accomplish this objective, we will randomly assign 6,000 patients with established T2D and ASCVD or high-risk for ASCVD in a 1:1 allocation to sodium-glucose cotransporter-... Read More
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
05/20/2024
Locations: Duke University Hospital, Durham, North Carolina
Conditions: Type2Diabetes, ASCVD
CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients
Recruiting
CREST-KT is a single-center, double-blinded, randomized trial of empagliflozin therapy in 72 kidney transplant recipients with (n=36) and without type 2 diabetes (n=36). After evenly dividing patients by type 2 diabetes diagnosis, patients will be randomized 2:1 to empagliflozin 10mg versus placebo.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/26/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Kidney Transplant; Complications, Diabetes Mellitus, Type 2